Answers are grounded in this paper and cite their sources.
BACKGROUND: Optimal clinical management of Helicobacter pylori (H. pylori) infection remains challenging considering its growing antimicrobial resistance. Tailored therapy might enhance treatment success. OBJECTIVE: The aim of this study was to analyse the effectiveness of PCR-guided therapy in H. pylori eradication, both as first-line and rescue therapy. METHODS: Data were obtained from the prospective, European multicentre Registry on H. pylori Management (Hp-EuReg). Adult PCR-tested (stool and gastric samples) H. pylori-infected patients registered at AEG-REDCap e-CRF were analysed. Effectiveness was evaluated by per protocol (PP) analysis. RESULTS: In total, 265 patients were included (130 treatment-naïve and 135 previously treated), 77% underwent gastric PCR-testing. In the first-line, 52% received 14-day prescriptions, and 31% high-dose proton pump inhibitors (PPIs). In the rescue-line, 55% were prescribed 14-day treatment, and 61% high-dose PPIs. Clarithromycin and fluoroquinolone resistance rates in the first-line were 31% and 33%, and 62% and 53% in the rescue-line, respectively. The overall effectiveness of PCR-guided therapy was 90% (95% first-line and 86% rescue-line). Most frequent first-line regimens were: quadruple concomitant therapy with clarithromycin+amoxicillin+metronidazole (48%), bismuth quadruple therapy as single-capsule containing bismuth+tetracycline+metronidazole (30%) and triple therapy with PPI+clarithromycin+amoxicillin (5.4%), providing an effectiveness of 95%, 97% and 100%, respectively. In the rescue-line, most frequent regimens were: single-capsule bismuth quadruple (43%), PPI-clarithromycin+amoxicillin+metronidazole (27%) and PPI-amoxicillin+moxifloxacin (11%), achieving 87%, 94% and 93% effectiveness, respectively. Adverse event incidence was 15%. CONCLUSION: PCR-guided therapy showed optimal results in all therapy lines. In regions with high (>15%) clarithromycin resistance, clarithromycin-based first-line therapy could still represent a good option provided pretreatment antibiotic sensitivity is assessed.
No takes yet. Share an insight, caveat, or question.
Milivojević et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: